CD4 and HIV infectious disease: In a follow up study where CD4+ T cell loss due to HIV infection was less marked (Figure S3A), VX-765 treatment did not significantly affect the abundance of CD4 + T cells in general including as a % of the total CD3 + T cells (Figure S3B).